Cretostimogene grenadenorepvec
BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS)
Key Facts
About CG Oncology
CG Oncology is a publicly traded, late-stage biopharma company singularly dedicated to transforming the treatment landscape for bladder cancer patients. Its core asset, cretostimogene grenadenorepvec, is an engineered oncolytic immunotherapy with a dual mechanism of action designed to selectively destroy cancer cells and stimulate a systemic anti-tumor immune response. The company is advancing this candidate through a pivotal Phase 3 program (PIVOT-006) for BCG-unresponsive NMIBC, with the goal of establishing it as a new backbone, bladder-sparing therapeutic. Backed by experienced leadership and investors, CG Oncology is positioned as a potential leader in urologic oncology.
View full company profileAbout CG Oncology
CG Oncology is a publicly traded, late-stage biopharma company singularly dedicated to transforming the treatment landscape for bladder cancer patients. Its core asset, cretostimogene grenadenorepvec, is an engineered oncolytic immunotherapy with a dual mechanism of action designed to selectively destroy cancer cells and stimulate a systemic anti-tumor immune response. The company is advancing this candidate through a pivotal Phase 3 program (PIVOT-006) for BCG-unresponsive NMIBC, with the goal of establishing it as a new backbone, bladder-sparing therapeutic. Backed by experienced leadership and investors, CG Oncology is positioned as a potential leader in urologic oncology.
View full company profileAbout CG Oncology
CG Oncology is a publicly traded, late-stage biopharma company singularly dedicated to transforming the treatment landscape for bladder cancer patients. Its core asset, cretostimogene grenadenorepvec, is an engineered oncolytic immunotherapy with a dual mechanism of action designed to selectively destroy cancer cells and stimulate a systemic anti-tumor immune response. The company is advancing this candidate through a pivotal Phase 3 program (PIVOT-006) for BCG-unresponsive NMIBC, with the goal of establishing it as a new backbone, bladder-sparing therapeutic. Backed by experienced leadership and investors, CG Oncology is positioned as a potential leader in urologic oncology.
View full company profileAbout CG Oncology
CG Oncology is a publicly traded, late-stage biopharma company singularly dedicated to transforming the treatment landscape for bladder cancer patients. Its core asset, cretostimogene grenadenorepvec, is an engineered oncolytic immunotherapy with a dual mechanism of action designed to selectively destroy cancer cells and stimulate a systemic anti-tumor immune response. The company is advancing this candidate through a pivotal Phase 3 program (PIVOT-006) for BCG-unresponsive NMIBC, with the goal of establishing it as a new backbone, bladder-sparing therapeutic. Backed by experienced leadership and investors, CG Oncology is positioned as a potential leader in urologic oncology.
View full company profile